These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
17. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. Ventura P; Bonkovsky HL; Gouya L; Aguilera-Peiró P; Montgomery Bissell D; Stein PE; Balwani M; Anderson DKE; Parker C; Kuter DJ; Monroy S; Oh J; Ritchie B; Ko JJ; Hua Z; Sweetser MT; Sardh E; Liver Int; 2022 Jan; 42(1):161-172. PubMed ID: 34717041 [TBL] [Abstract][Full Text] [Related]
18. Recovery of chronic motor neuropathy due to acute intermittent porphyria after givosiran treatment in a young boy: a case report. Mazzoli M; Ricci A; Vaudano AE; Marcacci M; Marchini S; Bergonzini P; Di Pierro E; Pischik E; Iughetti L; Pietrangelo A; Meletti S; Ventura P Eur Rev Med Pharmacol Sci; 2024 Apr; 28(8):3268-3274. PubMed ID: 38708485 [TBL] [Abstract][Full Text] [Related]
19. Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran. To-Figueras J; Wijngaard R; García-Villoria J; Aarsand AK; Aguilera P; Deulofeu R; Brunet M; Gómez-Gómez À; Pozo OJ; Sandberg S J Inherit Metab Dis; 2021 Jul; 44(4):961-971. PubMed ID: 33861472 [TBL] [Abstract][Full Text] [Related]
20. Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit? Petrides PE; Klein M; Schuhmann E; Torkler H; Molitor B; Loehr C; Obermeier Z; Beykirch MK Ann Hematol; 2021 Jul; 100(7):1685-1693. PubMed ID: 34050373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]